Synonym
Cgp 6809; Cgp6809; Cgp-6809.
IUPAC/Chemical Name
Ethyl-6-deoxy-3,5-di-O-methyl-6-(3-methyl-3-nitrosoureido)glucofuranoside
InChi Key
DRYAELVKAAODIB-ILAIQSSSSA-N
InChi Code
InChI=1S/C12H23N3O7/c1-5-21-11-8(16)10(20-4)9(22-11)7(19-3)6-13-12(17)15(2)14-18/h7-11,16H,5-6H2,1-4H3,(H,13,17)/t7-,8-,9-,10-,11+/m1/s1
SMILES Code
O([C@@H]([C@@H]1[C@H](OC)[C@@H](O)[C@H](O1)OCC)CNC(N(N=O)C)=O)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
321.33
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Creaven PJ, Cowens JW, Huben R, Petrelli N, Karakousis C, Traynor D. Phase I trial of a new nitrosourea, CGP 6809, given every 2 weeks. Cancer Chemother Pharmacol. 1989;23(4):266-7. PubMed PMID: 2924383.
2: Schieweck K, Stanek J, Kanter PM, Schmidt-Ruppin KH, Müller M, Matter A. CGP 6809, a sugar-containing nitrosourea derivative: pharmacological and physicochemical properties. Cancer Chemother Pharmacol. 1989;23(6):341-7. PubMed PMID: 2713956.
3: Fiebig HH, Widmer KH, Winterhalter BR, Löhr GW. CGP 6809--a new nitrosoureido-sugar derivative with activity in human tumor xenografts. Cancer Chemother Pharmacol. 1989;23(6):337-40. PubMed PMID: 2713955.
4: Creaven PJ, Madajewicz S, Cowens JW, Plager JE, Pendyala L, Mittelman A, Petrelli N, Karakousis C, Huben R, Takita H, et al. Phase I clinical trial of ethyl 6-deoxy-3,5-di-O-methyl 6-(3 methyl-3-nitrosoureido)-alpha-D-glucofuranoside (CGP 6809). Cancer Chemother Pharmacol. 1987;20(1):37-40. PubMed PMID: 3304687.
5: Bernacki RJ, Wilson GL, Mossman BT, Angelino N, Kanter PM, Korytnyk W. Therapeutic and diabetogenic potential of two newly synthesized nitrosoureido sugars. Cancer Res. 1985 Feb;45(2):695-702. PubMed PMID: 3881170.
6: Wagner I, Habs M, Schmähl D, Amberger H, Bachmann U. Chemotherapeutic studies on N-nitrosoacetoxymethyl-methylamine-and 1,2-dimethylhydrazine-induced colonic tumors in rats: monotherapy with 5-fluorouracil, ftorafur, CGP 6809, and CGP 15'720A. J Cancer Res Clin Oncol. 1982;104(1-2):115-31. PubMed PMID: 6813336.
